Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05036434 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Study acronym: ACCOMPLISH
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 31, 2025 to Feb 28, 2027
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Study completion date: Aug 31, 2026 to Feb 28, 2027
    v6
  2. Eligibility criteria expanded, about 106 wordsv5
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Study sites: 0 to 1
    • Collaborators expanded, about 3 words
    v4
  4. Start date: Nov 1, 2021 to Nov 15, 2021v3
  5. Eligibility criteria expanded, about 33 wordsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
* Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy * Trial Type : Single arm, prospective trial * Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib) * Treatment Groups : Single arm * Number of trial participants : 30
Trial Details
NCT Number NCT05036434
Lead Sponsor National Cancer Center, Korea
Collaborators: MSD Korea Ltd.
Conditions
(from sponsor)		 Adrenocortical Carcinoma
Related terms Adrenocortical Carcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov